Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
fair point. I think there was a £100k milestone/exclusivity payment due in H2 a few years ago that may be an ongoing annual payment. Obviously when total rev was 6 figures this was material. Now we are over £2m it's more of a nice to have, but i agree, some of these royalty payments may just 'drop' so are difficult to predict.
Shandy.
I still don't know how they work with partners to understand royalties expectations through the year through to finalisation, I remember even updates well after close still waiting for confirmation of royalties and whether they are that material anyway.
Next month sometime based on last year and previous Jan report prior to the FY being extended by 1 month
Is the h2 unaudited results due this week, or is that a guess based on previous years?
SOH was a little downbeat in that interview, or certainly not upbeat.
The rule of thumb is guidance can be 10% either way to be in line.
So if it was over £2.4m i think it would have been RNSed in Dec. It was not.
£2.3m ish will be ok with me and a positive 2022 outlook
Cheers aquae.
I think you're more in the ballpark, I'm always pessimistic and like surprise on the upside.
Will be interesting to see the margin, profit / loss, cash on revenues above 2.5m - and then hopefully to see potential for 22 with a range of potential revenue just on existing revenue streams.
AS - thanks for the useful revenue summary. With Covid delays persisting, H2 20 may not be as positive as hoped for. SOH indicated (in IM video) in line or possibly beating forecasts. By which, I assume he was referring to the £2.2m. Let's hope we can exceed £2.5m but not banking on it.
Hi skid, I would say revenue between £2.5-£3.0 M is a reasonable assumption based on my analysis of growth between the rolling (rather than direct h1/h2 cross year comparators) half years since 2019, which also clearly show the hit the company took in H2 2020 because of covid, and its subsequent recovery.
H1 2019 - £148,818
H2 2019 - £596,065 (301% growth)
H1 2020 - £744, 821 (25% growth)
H2 2020 - £778,426 (5% growth)
H1 2021 - £1,076,000 (38% growth)
Now throw in the subsequent drop in the share price from the 50s when there has only been good news since then and the fact the company is debt free so will not be impacted by interest rate rises on borrowing, and you can really see by how much this share is under valued and over sold.
I am looking for a bit more than £2.2, hopefully up to £2.5 and a better understanding of margin / open and where the breakeven point is.
the £2.2m revenue is for YE 31/12/21 - we should get the number in the next week or so.
To my knowledge i've not seen any guidance for 2022 onwards. Happy to be corrected
Interesting cenkos still have 2.2 for the current year.
Looking forward to an update on this with actuals, as well as current year f/cast which I would assume would be North of 3.5m without major transformative deals.
Well, let's hope the Antman is right
https://twitter.com/hashtag/sweetbiotix
Ant_Man
@online_antz
·
17 Jan
#OPTI stars are aligning for OPTI’s #Sweetbiotix revolutionary ’sweet’ fibre technology, as the industry look for innovative - highly disruptive technology for the $120bln pa Sugar/Sweetener market -Gamechanger!
Tate & Lyle pledges to take action on fibre
bakeryandsnacks.com
Tate & Lyle pledges to take action on fibre
The ingredients specialist is the latest to sign up to the UK’s Food and Drink Federation’s (FDF) Action on Fibre.
Ant_Man
@online_antz
·
29 Dec 2021
#OPTI 45p paid??
?3x £1m pa deals signed in Dec alone
?100% YoY sales growth
?Revolutionary 2nd Generation technology #Sweetbiotix deal expected in Jan
?SEED (Partner) IBS trial result’s due Jan/Feb
?Low cost business model (likely to be Profitable in 2022!)
I agree that the 2021 eoy results (unaudited expected next month) will act as a major catalyst to the sp.
Bearing in mind that the half year revenue had grown to £ 1.076M , with the following further second half revenue growth factors, I expect the final revenue figure to be circa £3M :
I. Growing sales with existing partners by extending product lines and territories. These include:-
a. The launch of Bioslim, a Very Low-Calorie Diet (VLCD) weight management product with Arrotex Pharmaceutials, Australia's largest privately owned pharmaceutical company and the Optiman brand containing OptiBiome in July 2021 with Optipharm.
b. The extension of Holland & Barretts SlimExpert own brand range of SlimBiome® from three to eight in March 2021.
c. Territory expansion for DS-01 containing LPLDL® with Seed Health to support their ambitious growth plans.
II. Growing sales with large partners in key strategic markets (e.g India, China, USA etc).
As in previous years, there was no substantive contribution in the period from license or royalty payments which tend to be received in the second half of the year.
It appears to me that SOH intention to step up IR is now being demonstrated with articles in Mail, better coverage by Cenkos.
The latest.trial may catch attention of big pharma or health company. Reinforces old maxim you are what you eat.
Another positive is the company is increasing size of team as it gets greater confidence over sales volumes it can cope with larger expense base.
Looking forward to 2021 results and 2022 forecasts which should be catalysts in growth.
Indicators other than share price look positive.